Researchers at University of the Pacific in Stockton have developed a long-acting opioid overdose-reversal drug-delivery ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

P.E.I.’s chief public health officer says the province has decided to pause the establishment of a supervised injection site ...

The biosimilar's safety and immunogenicity profiles were found to be comparable to those of the reference product in the ...

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

The subcutaneous autoinjector, named lecanemab-irmb, is designed as a weekly treatment option for maintenance dosing in patients who have already completed the biweekly intravenous initiation phase.

The reported side-effects of KORTUC have so far been limited to discomfort at the injection site for up to 24 hours. Professor Karol Sikora, a clinical oncologist based in London, is however cautious.

The investigation has enrolled 532 patients with relapsed/refractory myeloma across 252 global sites. Eligible adult patients who ... device that is thinner compared with commonly used subcutaneous ...

Nucala (mepolizumab) is a brand-name subcutaneous injection that comes ... Before injecting Nucala, you’ll need to clean the injection site with an alcohol swab and let it air-dry.